This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information ...

The biologic drug tocilizumab (Actemra) has a new competitor since its patent recently expired in the U.S., although it is not yet available in this country. Having another option to treat sJIA is a ...